AngioDynamics (NASDAQ:ANGO) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $0.16 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.16, Bloomberg Earnings reports. The business had revenue of $86.70 million during the quarter, compared to analyst estimates of $88.15 million. AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The company’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share.

Shares of AngioDynamics (NASDAQ:ANGO) opened at $16.41 on Thursday. AngioDynamics has a 12 month low of $14.80 and a 12 month high of $18.85. The firm has a market cap of $615.36, a price-to-earnings ratio of 109.41, a PEG ratio of 1.72 and a beta of 1.04. The company has a quick ratio of 1.48, a current ratio of 2.34 and a debt-to-equity ratio of 0.17.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Municipal Employees Retirement System of Michigan grew its holdings in shares of AngioDynamics by 13.3% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,160 shares of the medical instruments supplier’s stock worth $132,000 after purchasing an additional 960 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of AngioDynamics in the third quarter worth about $143,000. Acrospire Investment Management LLC grew its holdings in shares of AngioDynamics by 3.7% in the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 317 shares during the last quarter. Trexquant Investment LP bought a new position in shares of AngioDynamics in the third quarter worth about $175,000. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in shares of AngioDynamics by 54.9% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 3,900 shares during the last quarter. 95.23% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts recently issued reports on the stock. TheStreet downgraded shares of AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price target on shares of AngioDynamics in a research note on Sunday, October 8th. Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Tuesday, October 3rd. Finally, KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a research note on Friday, September 29th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. AngioDynamics currently has an average rating of “Hold” and a consensus price target of $18.60.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/04/angiodynamics-ango-releases-earnings-results.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Earnings History for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.